广州白云山医药集团股份有限公司 关于子公司《药品生产许可证》变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"） 全资子公司广州白云山中一药业有限公司（以下简称"中一药业"） 收到广东省药品监督管理局核准签发的《药品生产许可证》，同意 中一药业接受广州白云山奇星药业有限公司（以下简称"奇星药业"） 委托生产复方余甘子利咽含片（国药准字 B20020422）。现将相关情 况公告如下： 一、《药品生产许可证》基本情况 企业名称：广州白云山中一药业有限公司 许可证编号：粤 20160046 分类码：AhzxBzCz 注册地址：广州市黄埔区云埔一路 32 号 发证机关：广东省药品监督管理局 有效期至：2025 年 8 月 20 日 生产地址和生产范围： 证券代码：600332 证券简称：白云山 公告编号：2023－052 同意中一药业接受奇星药业委托生产复方余甘子利咽含片（国 药准字 B20020422），受托生产车间:制造一部、制造二部、制造三 部、南村提取车间，受托 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2023年10月31日 狀態: 新提交 本月底法定/註冊股本總額： RMB 1,625,790,949 II. 已發行股份變動 致：香港交易及結算所有限公司 公司名稱: 廣州白雲山醫藥集團股份有限公司 （「本公司」） 呈交日期: 2023年11月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 | 00874 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 219,900,000 | RMB | | 1 RMB | | 219,900,000 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 219,900,000 | RMB | | 1 RMB | | ...

Financial Performance - The company's operating revenue for Q3 2023 reached CNY 18,214,219 thousand, representing a year-on-year increase of 3.58%[6] - The net profit attributable to shareholders for Q3 2023 was CNY 980,002 thousand, reflecting a growth of 10.81% compared to the same period last year[6] - The net profit after deducting non-recurring gains and losses was CNY 840,145 thousand, with a year-on-year increase of 0.78%[7] - The basic earnings per share for Q3 2023 was CNY 0.603, up by 10.81% year-on-year[7] - The total operating revenue for the first three quarters of 2023 reached ¥58,184,549,516.02, an increase of 6.5% compared to ¥54,805,915,266.27 in the same period of 2022[20] - The net profit for the first three quarters of 2023 was ¥3,928,725,209.12, compared to ¥3,684,732,596.24 in the same period of 2022, representing an increase of 6.6%[21] - The earnings per share (EPS) for the third quarter of 2023 was ¥2.332, up from ¥2.137 in the same quarter of the previous year[22] Assets and Liabilities - The total assets at the end of the reporting period amounted to CNY 74,353,331 thousand, showing a decrease of 0.42% from the end of the previous year[7] - The total liabilities as of the end of the third quarter of 2023 amounted to ¥37,977,384,691.70, a decrease from ¥41,027,440,697.52 at the end of the previous year[19] - The equity attributable to shareholders increased to CNY 34,660,070 thousand, marking an increase of 8.09% compared to the end of the previous year[7] - The total equity attributable to shareholders of the parent company increased to ¥34,660,070,222.82 from ¥32,065,124,770.91 year-over-year, marking a growth of 8.1%[19] Cash Flow - The net cash flow from operating activities for the year-to-date was CNY 901,626 thousand, down by 72.67% year-on-year[11] - The net cash flow from operating activities for Q3 2023 was approximately ¥901.63 million, a significant decrease from ¥3.30 billion in Q3 2022[25] - The total cash inflow from investment activities in Q3 2023 was approximately ¥2.36 billion, a substantial increase from ¥253.22 million in Q3 2022[26] - The net cash flow from financing activities in Q3 2023 was approximately -¥916.78 million, compared to a positive cash flow of ¥1.29 billion in Q3 2022[26] - The total cash and cash equivalents at the end of Q3 2023 stood at approximately ¥18.59 billion, down from ¥19.73 billion at the end of Q3 2022[26] Operational Metrics - The company reported non-operating income of CNY 139,857 thousand for Q3 2023, compared to CNY 352,596 thousand for the same period last year[11] - The company has experienced an increase in cash payments for goods and services, impacting the net cash flow from operating activities[11] - Current assets totaled RMB 52.92 billion, down from RMB 57.06 billion at the end of 2022, primarily due to a decrease in cash and cash equivalents[17] - Accounts receivable increased to RMB 16.52 billion from RMB 14.86 billion, indicating a growth of approximately 11.1% year-over-year[16] - Inventory decreased to RMB 9.66 billion from RMB 10.67 billion, reflecting a reduction of about 9.5%[17] - Non-current assets rose to RMB 21.43 billion from RMB 17.60 billion, representing an increase of approximately 21.5%[17] - Short-term borrowings decreased to RMB 8.16 billion from RMB 8.54 billion, a decline of about 4.4%[17] - Accounts payable increased to RMB 12.62 billion from RMB 11.20 billion, showing a growth of approximately 12.7%[17] - The company reported a significant increase in other receivables, rising to RMB 1.08 billion from RMB 917.24 million, an increase of about 17.5%[17] Research and Development - Research and development expenses for the first three quarters of 2023 were ¥579,480,533.51, down from ¥664,386,145.53 in the same period of 2022, indicating a reduction of 12.8%[20] - The company has not disclosed any new product launches or technological advancements during this quarter[16] Market and Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[23] - There are no updates on market expansion or mergers and acquisitions in the current report[16]

Financial Performance - Operating revenue for Q3 2023 reached RMB 18,214,219 thousand, an increase of 3.58% year-on-year[2] - Net profit attributable to shareholders was RMB 980,002 thousand, reflecting a growth of 10.81% compared to the same period last year[2] - Net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 840,145 thousand, with a slight increase of 0.78% year-on-year[2] - The basic earnings per share for Q3 2023 was RMB 0.603, up by 10.81% year-on-year[2] - Total operating revenue for the first three quarters of 2023 reached RMB 58.18 billion, an increase of 6.3% compared to RMB 54.81 billion in the same period of 2022[14] - Operating profit for the first three quarters of 2023 was RMB 4.76 billion, up from RMB 4.46 billion in the same period of 2022, reflecting a growth of 6.6%[15] - Net profit attributable to shareholders of the parent company for the first three quarters of 2023 was RMB 3.79 billion, compared to RMB 3.47 billion in 2022, representing an increase of 9.3%[15] - Basic and diluted earnings per share for the first three quarters of 2023 were both RMB 2.332, up from RMB 2.137 in the same period of 2022[16] - The total comprehensive income attributable to shareholders of the parent company for the first three quarters of 2023 was RMB 3.79 billion, compared to RMB 3.48 billion in 2022, an increase of 8.5%[16] Assets and Liabilities - Total assets at the end of the reporting period amounted to RMB 74,353,331 thousand, a decrease of 0.42% from the end of the previous year[2] - Total assets increased to RMB 74.35 billion in 2023 from RMB 74.67 billion in 2022, indicating a slight decrease of 0.4%[13] - Total liabilities decreased to RMB 37,977,384,691.70 from RMB 41,027,440,697.52, a reduction of 7.5%[11] - The company’s total liabilities and equity amounted to RMB 36.38 billion in 2023, up from RMB 33.64 billion in 2022, reflecting an increase of 8.2%[13] Shareholder Information - Shareholders' equity attributable to the parent company increased to RMB 34,660,070 thousand, representing an increase of 8.09% year-on-year[2] - The company had a total of 91,342 common shareholders at the end of the reporting period[4] - The largest shareholder, Guangzhou Pharmaceutical Group Co., Ltd., holds 45.04% of the shares[5] - The company reported a total of 732,305,103 shares held by Guangzhou Pharmaceutical Group Co., Ltd., the largest shareholder[6] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date was RMB 901,626 thousand, showing a significant decrease of 72.67% year-on-year[4] - Operating cash inflow for the first three quarters of 2023 was RMB 53.47 billion, a slight increase from RMB 52.59 billion in the same period of 2022, representing a growth of 1.68%[17] - Cash outflow from operating activities totaled RMB 52.57 billion in 2023, compared to RMB 49.29 billion in 2022, indicating an increase of 6.56%[18] - Net cash flow from operating activities decreased to RMB 901.63 million in 2023, down 72.66% from RMB 3.30 billion in 2022[18] - Cash inflow from investment activities was RMB 2.36 billion in 2023, significantly higher than RMB 253.22 million in 2022[18] - Net cash flow from investment activities was negative at RMB 2.21 billion in 2023, an improvement from a loss of RMB 5.87 billion in 2022[18] - Cash inflow from financing activities was RMB 10.80 billion in 2023, slightly lower than RMB 11.38 billion in 2022, a decrease of 5.06%[19] - Net cash flow from financing activities turned negative at RMB 916.78 million in 2023, compared to a positive flow of RMB 1.29 billion in 2022[19] - The ending cash and cash equivalents balance as of September 2023 was RMB 18.59 billion, down from RMB 19.73 billion at the end of September 2022, a decrease of 5.78%[19] Current Assets and Receivables - As of September 30, 2023, total current assets amounted to RMB 52,924,980,357.93, a decrease of 7.5% from RMB 57,064,311,513.29 on December 31, 2022[8] - Cash and cash equivalents decreased to RMB 19,873,967,228.77 from RMB 22,499,552,770.75, representing a decline of 11.5%[8] - Accounts receivable increased to RMB 16,521,846,517.80, up 11.2% from RMB 14,857,591,768.49[8] - Total non-current assets reached RMB 21,428,350,404.03, an increase of 21.5% compared to RMB 17,600,987,263.45 at the end of 2022[9] - The total amount of accounts payable rose to RMB 12,620,557,642.25, an increase of 12.7% from RMB 11,200,347,828.21[10] Research and Development - Research and development expenses for the first three quarters of 2023 were RMB 579.48 million, down from RMB 664.39 million in 2022, a decrease of 12.8%[14] - The company has not disclosed any significant new product developments or market expansion strategies during the reporting period[7] Foreign Currency Impact - The company recorded a net foreign currency translation difference of RMB 5.07 million in the first three quarters of 2023, compared to RMB 17.80 million in 2022, indicating a decrease of 71.5%[16] - The impact of exchange rate changes on cash and cash equivalents was positive at RMB 6.75 million in 2023, compared to a negative impact of RMB 876.30 thousand in 2022[19]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 須予披露的交易：出售應收賬款 本次交易 基礎資產買賣協議（第二期）項下第六次《新增基礎資產交割確認函》之交易 如本公司日期為2021年9月10日的公告第3節及日期為2023年2月1日公告第2節所披露，於2021年 8月13日，廣州醫藥與興證資管簽訂基礎資產買賣協議（第二期），發行規模為人民幣10億元，其 後，廣州醫藥與興證資管根據基礎資產買賣協議（第二期）分別訂立一次《交割確認函》及六次《新 增基礎資產交割確認函》，以進行基礎資產買賣協議（第二期）項下的交易並確認廣州醫藥向興證 資管出售的資產和廣州醫藥就此而收到的購買價款。 於2023年10月30日，廣州醫藥與興證資管根據基礎資產買賣協議（第三期）簽訂《新增基礎資產交 割確認函》，確認向興證資管出售第三次新增基礎資產，並收到購買價款人民幣687,592,481.77 元。 上市規則的含義 本公司根據上市規則第14.07條單獨計算有關本次交易的所有適用百 ...

证券代码：600332 证券简称：白云山 公告编号：2023-051 广州白云山医药集团股份有限公司 第九届监事会第三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 广州白云山医药集团股份有限公司（以下简称"本公司"）第九届监事 会第三次会议（以下简称"会议"）于 2023 年 10 月 16 日以电邮方式发出 通知，于 2023 年 10 月 30 日以通讯形式召开。本次会议应参加表决监事 3 人，实际参加表决监事 3 人。会议的召集、召开符合《公司法》及《公司 章程》的规定。 经监事审议、表决，会议审议通过如下议案： 一、本公司 2023 年第三季度报告； 表决结果：同意票 3 票，反对票 0 票，弃权票 0 票，审议通过本议案。 二、对本公司 2023 年第三季度报告的书面审核意见。 表决结果：同意票 3 票，反对票 0 票，弃权票 0 票，审议通过本议案。 特此公告。 广州白云山医药集团股份有限公司监事会 2023 年 10 月 30 日 ...

证券代码：600332 证券简称：白云山 公告编号：2023－050 广州白云山医药集团股份有限公司 药品通用名称：注射用头孢呋辛钠 受理号：CYHB2350242 剂型：注射剂 规格： 0.5g（按C₁₆H₁₆N₄O8S计） 注册分类：化学药品 上市许可持有人名称：广州白云山天心制药股份有限公司，地址： 广州市海珠区滨江东路808号 生产企业：广州白云山天心制药股份有限公司，地址：广州市海 珠区滨江东路808号 关于控股子公司药品通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"） 控股子公司广州白云山天心制药股份有限公司（以下简称"天心药业"） 收到国家药品监督管理局核准签发的《药品补充申请批准通知书》（通 知书编号：2023B05073），注射用头孢呋辛钠（0.5g）已通过仿制药 质量和疗效一致性评价。现将有关情况公告如下： 一、药品的基本情况 原药品批准文号：国药准字H20023628 品质量标准；2.变更直接接触药品的包装材料及容器。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 董事會會議召開日期 廣州白雲山醫藥集團股份有限公司（「本公司」）董事會（「董事會」）茲通告謹定於2023年10月30日（星期 一）舉行董事會會議，藉以審議及批准本公司及其附屬公司截至2023年9月30日止九個月未經審計財 務業績及處理其他事項（如有）。 廣州白雲山醫藥集團股份有限公司 董事會 中國廣州，2023年10月16日 於本公告日，本公司董事會成員包括執行董事李楚源先生、楊軍先生、程寧女士、劉菊妍女士、 張春波先生、吳長海先生與黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與 孫寶清女士。 | PATH: T:\01_Announcement\23102407-GBP-PA\23102407-GBP-PA(c) | PAGE: (1 / 1) | | DRAFT: | DRAFT: 1st Proof | USER: Proof | USER: carlchanwh | MODIFY: ...

致：香港交易及結算所有限公司 公司名稱: 廣州白雲山醫藥集團股份有限公司 （「本公司」） 呈交日期: 2023年10月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 | 00874 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 219,900,000 | RMB | | 1 | RMB | | 219,900,000 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 219,900,000 | RMB | | 1 | RMB | | 219,900,000 | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | -- ...

证券代码：600332 证券简称：白云山 广州白云山医药集团股份有限公司 投资者关系活动记录表 ■特定对象调研 £分析师会议 £媒体采访 £业绩说明会 投资者关系活 动类别 □新闻发布会路演活动 □现场参观 £其他 线上会议、现场调研 召开方式 时间 2023年9月19日至9月25日 地点 线上、公司 董事会秘书黄雪贞女士、证券事务代表黄瑞媚女士、董事会秘 公司参与人员 书室经理郭云倩女士 ...